Ceretype Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Later Stage VC
- Investors
-
7
Ceretype General Information
Description
Developer of a brain imaging technology designed to revolutionize neuropsychiatric healthcare. The company's technology helps to improve drug discovery and patient care through its ability to subtype and classify the human brain on a neurobiological level and offers therapeutic strategies to address psychiatric illness and central nervous system disorders, enabling medical professionals to pioneer precision psychiatry.
Contact Information
Website
www.ceretype.comCorporate Office
- 1 Broadway
- 14th Floor
- Cambridge, MA 02142
- United States
Corporate Office
- 1 Broadway
- 14th Floor
- Cambridge, MA 02142
- United States
Ceretype Timeline
Ceretype Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 18-Mar-2026 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 29-Sep-2025 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 11-Jul-2024 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 27-Feb-2023 | $100K | $2.3M | Completed | Generating Revenue | |
| 1. Seed Round | 24-Oct-2021 | $2.2M | $2.2M | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Ceretype Patents
Ceretype Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024381209-A1 | Autocalibrating multi-echo functional magnetic resonance imaging | Pending | 15-Nov-2023 | ||
| EP-4809313-A1 | Autocalibrating multi-echo functional magnetic resonance imaging | Pending | 15-Nov-2023 | ||
| WO-2025106746-A1 | Autocalibrating multi-echo functional magnetic resonance imaging | Inactive | 15-Nov-2023 | ||
| EP-4712848-A2 | Multi-echo fmri reports | Pending | 19-May-2023 | ||
| US-20260321373-A1 | Multi-echo fmri reports | Pending | 19-May-2023 | G16H15/00 |
Ceretype Signals
Ceretype Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cedar Street Group | Venture Capital | Minority | ||
| One Mind | Accelerator/Incubator | Minority | ||
| Catalytic Impact Foundation | Not-For-Profit Venture Capital | Minority | ||
| Impact Assets | Impact Investing | Minority | ||
| JLS Fund | Venture Capital | Minority |
Ceretype FAQs
-
When was Ceretype founded?
Ceretype was founded in 2020.
-
Where is Ceretype headquartered?
Ceretype is headquartered in Cambridge, MA.
-
What is the size of Ceretype?
Ceretype has 6 total employees.
-
What industry is Ceretype in?
Ceretype’s primary industry is Decision/Risk Analysis.
-
Is Ceretype a private or public company?
Ceretype is a Private company.
-
What is Ceretype’s current revenue?
The current revenue for Ceretype is .
-
How much funding has Ceretype raised over time?
Ceretype has raised $2.7M.
-
Who are Ceretype’s investors?
Cedar Street Group, One Mind, Catalytic Impact Foundation, Impact Assets, and JLS Fund are 5 of 7 investors who have invested in Ceretype.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process